

ASX RELEASE

1 NOVEMBER 2024

NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES**AMPLIA SUCCESSFULLY COMPLETES INSTITUTIONAL PLACEMENT AND INSTITUTIONAL ENTITLEMENT OFFER AND ANNOUNCES UNDERWRITING OF RETAIL ENTITLEMENT OFFER**

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the successful completion of the institutional placement (**Placement**) and the institutional component (**Institutional Entitlement Offer**) of its 1 for 6.45 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer** and, together with the Placement, the **Offer**) of new fully paid ordinary shares in Amplia (**New Shares**), details of which were announced to ASX on 30 October 2024.

New Shares are being offered with free attaching options on the basis of three options for every four New Shares issued (**Attaching Options**). The Attaching Options will be exercisable for New Shares at an exercise price of \$0.1725 and will expire on 31 October 2027. Amplia will apply for quotation of the Attaching Options on the ASX. Quotation of the Attaching Options is subject to the Company satisfying ASX’s quotation requirements.

The Company is also pleased to announce that the retail component of the entitlement offer (**Retail Entitlement Offer**) is now fully underwritten.

The Placement and Institutional Entitlement Offer (together, the **Institutional Offer**) closed on 31 October 2024. The Institutional Offer will raise gross proceeds of ~A\$9.9 million at the Offer Price of A\$0.115 per New Share, consisting of approximately A\$7.8 million under the Placement, ~\$0.3 million under the Director Placement and approximately A\$1.8 million under the Institutional Entitlement Offer.¹

The Institutional Offer attracted strong demand from existing institutional shareholders of the Company, and also introduced several new institutional investors to the Amplia register.

Dr Warwick Tong, Chairman of Amplia, commented:

“The team at Amplia is delighted with the success of this capital raise and grateful for the support shown by institutional investors. Amplia welcomes new institutional investors participating in this raise and looks forward to support from the Company’s retail investors.”

Dr Chris Burns, Managing Director of Amplia, commented:

“The success of this capital raise is very significant in terms of Amplia achieving its stated goals in pancreatic cancer of completing the ACCENT trial with the Company’s lead compound narmafotinib, and initiating a trial of narmafotinib in the US in combination with FOLFIRINOX.”

New Shares subscribed for under the Institutional Offer are expected to be settled on Wednesday, 6 November 2024 and to be issued, together with Attaching Options, on Thursday, 7 November 2024, other than the Director Placement of \$325,000 worth of New Shares which is subject to shareholder

¹ The take up rate under the Institutional Entitlement Offer was approximately 76% and the balance has been placed via the shortfall bookbuild.

approval. New Shares issued under the Institutional Offer will rank equally with existing fully paid ordinary shares in Amplia as at their date of issue.

Amplia's ordinary shares will recommence trading on ASX on an ex-entitlements basis from market open today.

Replacement Prospectus

Amplia has today lodged a replacement prospectus (**Prospectus**) with ASIC, updating the original prospectus for the Placement and Entitlement Offer dated 30 October 2024.

The key differences between the Prospectus and the original prospectus are to disclose the Company's entry into the Underwriting Agreement, pursuant to which the Retail Entitlement Offer will be fully underwritten by Bell Potter Securities Limited and Taylor Collison Limited and to include the offer of up to 5,433,750 options to sub-underwriters of the Retail Entitlement Offer on the same terms as the Attaching Options are being offered to participants in the Placement and Entitlement Offer. The offer of options to sub-underwriters of the Retail Entitlement Offer is conditional on shareholder approval for the purposes of Listing Rule 7.1.

Retail Entitlement Offer

Eligible retail shareholders with a registered address in Australia or New Zealand as at the Record Date (**Eligible Retail Shareholders**) have the opportunity to take up their entitlement for New Shares at the Offer Price, together with Attaching Options, on the terms and conditions set out in the Prospectus.

The fully underwritten Retail Entitlement Offer will open on Wednesday, 6 November 2024 and is anticipated to close on Friday, 22 November 2024.

Eligible Retail Shareholders can choose to take up all, part, or none of their entitlements. Furthermore, the Retail Entitlement Offer will include a 'Top Up Facility' under which Eligible Retail Shareholders who take up their entitlement in full may also apply for additional New Shares (and Attaching Options) up to a maximum of 100% of their entitlement (**Top-Up Facility**). Further details are provided in the Prospectus and the personalized Entitlement and Acceptance Form.

Any shortfall from the Retail Entitlement Offer will be subscribed by the Underwriters as described in the Prospectus.

New Shares and Attaching Options under the Retail Entitlement Offer are expected to be issued on Friday 29 November 2024. Please note that Amplia's retail shareholders with a registered address outside Australia or New Zealand on the Record Date are ineligible to participate in the Retail Entitlement Offer for the reasons set out in the Prospectus. Securityholders who are on the register on the Record Date will be notified by ATX if they are ineligible to participate in the Entitlement Offer.

Further details regarding how to apply for New Shares in the Retail Entitlement Offer is set out in the Prospectus and will be provided in your personalized Entitlement and Acceptance Form.

Attaching Options

New Shares issued under the Retail Entitlement Offer will be offered with three (3) free attaching options for every four (4) New Shares issued ("Attaching Options"). The Attaching Options will have an exercise price of A\$0.1725 and will expire on 31 October 2027.

Bell Potter Securities Limited (ACN 006 390 772, AFSL 243480) (**Bell Potter**) and Taylor Collison Limited (ACN 008 172 450, AFSL 247083) (**Taylor Collison**) are acting as joint lead managers and bookrunners for the Placement and Institutional Entitlement Offer, and Underwriters to the Retail

Entitlement Offer (**Joint Lead Managers and Underwriters**).

Key dates for Capital Raise

The Capital Raise will be conducted according to the following indicative timetable:

Event	Date
Trading halt and announcement of Capital Raise	Wednesday, 30 October 2024
Announcement of results of Placement and Institutional Entitlement Offer and trading halt lifted Lodgement of replacement Prospectus with ASIC and ASX	Friday, 1 November 2024
Record date for Entitlement Offer (7.00pm Sydney time)	Friday, 1 November 2024
Settlement of New Shares issued under the Placement and Institutional Entitlement Offer	Wednesday, 6 November 2024
Entitlement and Acceptance Forms made available to Eligible Retail Shareholders and Retail Entitlement Offer opens	Wednesday, 6 November 2024
Issue of New Shares under the Placement and Institutional Entitlement Offer and Attaching Options under the Institutional Entitlement Offer	Thursday, 7 November 2024
Retail Entitlement Offer closes (5.00pm Sydney time)	Friday, 22 November 2024
Announcement of results of Retail Entitlement Offer	Wednesday, 27 November 2024
Settlement of Retail Entitlement Offer	Thursday, 28 November 2024
Issue of New Shares and Attaching Options under the Retail Entitlement Offer	Friday, 29 November 2024
Commencement of trading of New Shares issued under the Retail Entitlement Offer	Monday, 2 December 2024
EGM to approve the Director Placement and issue of Attaching Options to Placement participants and retail sub-underwriters	On or around Monday, 9 December 2024
Allotment of Attaching Options to Placement participants and retail sub-underwriters and New Shares and Attaching Options to Directors (subject to Shareholder approval)	On or around Tuesday, 10 December 2024
Commencement of trading of Attaching Options (subject to satisfaction of quotation conditions)	On or around Thursday, 12 December 2024

* Please note the dates set out above are indicative only and are subject to change. All dates and times are references to Sydney, Australia time.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

About Narmafotinib

Narmafotinib (AMP945) is the Company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in

solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer study, and is currently in an open-label Phase 2a trial in pancreatic cancer where a combination of narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety, tolerability and efficacy.

About the ACCENT Trial

The ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The ACCENT trial explores the use of narmafotinib in combination with standard-of-care chemotherapy of gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, identified a 400 mg oral daily dose of narmafotinib, given in the days preceding regular chemotherapy infusion, as safe and well tolerated.

This second stage (Phase 2a), of the trial is designed to assess drug efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed.

More information about the ACCENT trial, including a list of participating sites, can be found via the Amplia Therapeutics [website](#) and at ClinicalTrials.gov under the identifier [NCT05355298](#).

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).